Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Clinical trial NCT05595889 · UNKNOWN
Trial details
- NCT number
- NCT05595889
- Sponsor
- Fujian Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-01
- Primary completion
- 2024-09-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.